Imported and sold Lowacol (for cholelithiasis treatment) and Roitin (for urolithiasis treatment), Japan’s first internal lithiasis treatment agents, from West Germany.

Launched Haemolind, Japan’s the first sublingual tablet for hemorrhoids. Campaigned for commercials in the mass media.

Established the Kyobashi Factory in Shinkita-cho, Joto-ku, Osaka. Expanded and strengthened the field of internal drugs by manufacturing tablets and capsules, among others.

Developed and launched hemodialysis solution "Fuso," the same year as Japan’s first dialysate . The photo shows the hemodialysis solution "Fuso."

Constructed the state-of-the-art modern factory with seven floors above and two floors below the ground at the Joto Factory site, in compliance with Good Manufacturing Practices (GMP).

Launched Cernilton tablets, for treating prostate disease.

The first dialysate, "Kindaly 1 and 2" of the Kindaly ® series of dialysate for hemodialysis, was developed and launched, which continues to the present day.

Listed on the Second Section of the Osaka Securities Exchange. Capital: ¥ 360 million , sales: ¥ 5.325 billion.

In the same year, construction of the Transport Center, six floors above and two floors below ground was completed at the Joto Factory site.

Developed and launched the Stack Hemodialysis Machine FA-11 and then the FA-21, opening up a new field of dialysis and paving the way into the medical equipment market.